晚期肝细胞癌免疫联合转化序贯外科治疗专家共识(2026版)解读
该共识由相关学术组织基于2024版共识发布后的最新循证证据与国内临床实践经验,组织多领域专家修订更新,旨在规范晚期肝细胞癌免疫联合转化治疗序贯外科治疗的全流程管理,指导临床医师制订合理诊疗决策,最大化提升患者治疗获益。
要点
- 初诊晚期肝细胞癌缺乏有效根治手段且预后差,免疫检查点抑制剂联合方案可提高客观缓解率并延长生存。
- 规范化转化治疗后部分初始不可切除患者可序贯根治性肝切除或肝移植,获得稳定长期生存获益。
- 共识更新旨在规范免疫联合转化序贯外科治疗全流程管理,指导临床决策并提升综合诊疗水平。
核心结论
- 基于免疫检查点抑制剂的联合治疗方案在提高晚期肝细胞癌客观缓解率、延长生存期方面表现出临床优势。
- 经规范化转化治疗后部分初始不可切除的晚期肝细胞癌患者可序贯接受根治性肝切除或肝移植,最终获得稳定的长期生存获益。
研究设计与样本
- 相关学术组织结合2024版共识发布以来的最新循证证据与国内临床实践经验,组织多领域专家对共识内容进行修订与更新。
主要发现
- 肝细胞癌患者初诊时多已处于晚期阶段,缺乏有效的根治性治疗手段,整体预后较差。
- 免疫检查点抑制剂联合治疗方案可提高疾病客观缓解率并延长患者生存期。
- 规范化转化治疗后部分初始不可切除的晚期肝细胞癌患者可序贯接受根治性肝切除或肝移植。
临床怎么用
- 临床应依据共识规范晚期肝细胞癌免疫联合转化治疗序贯外科治疗的全流程管理。
- 对初始不可切除的晚期肝细胞癌患者,经规范化转化治疗后评估序贯根治性肝切除或肝移植的可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients diagnosed with hepatocellular carcinoma (HCC) are often already at an advanced stage at the time of initial diagnosis, with limited effective curative treatment options available and a generally poor overall prognosis. In recent years, combination therapy regimens incorporating immune checkpoint inhibitors have demonstrated clinical advantages in improving the objective response rate and prolonging patient survival. Following standardized transition therapy, some patients with initially unresectable advanced HCC may subsequently undergo curative hepatectomy or liver transplantation, ultimately achieving stable long-term survival benefits. To further standardize the comprehensive management of the sequential surgical treatment approach in the immunotherapy-based transition therapy for advanced HCC, relevant academic organizations have convened multidisciplinary experts to revise and update the content of this consensus, drawing upon the latest evidence-based data since the publication of the "Expert consensus on the sequential surgery following conversion therapy based on the combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma(2024 edition)" and incorporating domestic clinical practice experience. This initiative aims to guide clinicians in making informed diagnostic and therapeutic decisions, maximize patient treatment benefits, and contribute to the continuous advancement of comprehensive HCC management standards in China. 肝细胞癌患者在初诊时多已处于晚期阶段,缺乏有效的根治性治疗手段,整体预后较差。近年来,基于免疫检查点抑制剂的联合治疗方案在提高疾病客观缓解率、延长患者生存期方面表现出临床优势。经规范化转化治疗后,部分初始不可切除的晚期肝细胞癌患者可序贯接受根治性肝切除或肝移植治疗,最终获得稳定的长期生存获益。为了进一步规范晚期肝细胞癌免疫联合转化治疗序贯外科治疗的全流程管理,相关学术组织结合《晚期肝细胞癌免疫靶向联合转化序贯外科治疗专家共识(2024版)》发布以来的最新循证证据与国内临床实践经验,组织多领域专家对共识内容进行了修订与更新,以期指导临床医师制订合理诊疗决策,最大化提升患者治疗获益,推动我国肝细胞癌综合诊疗水平持续提升。.
引用
- [Expert consensus on immunotherapy-based combination conversion therapy followed by sequential surgery for advanced hepatocellular carcinoma(2026 edition)]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 42765409. doi:10.3760/cma.j.cn112139-20260803-00334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。